Sickle-cell patient who joined multiple trials urges plain language consent and family support

At the Belmont commemoration, Ted Nicolas described his experience as a clinical-trial volunteer for sickle cell therapies and urged researchers to make consent documents understandable and support participants practically. He said clinicians and trial teams should explain risks plainly and recommended journaling and family involvement to help participants communicate symptoms to researchers.

Nicolas, who said he was cured following a stem-cell trial he joined, recounted first learning about trials from clinicians and later seeking information online and from patient groups. "Plain language is a great help," he said, urging researchers to make consent and study processes accessible to people without medical training. His remarks illustrated the human side of ethical protections discussed by the panel and underscored how recruitment and retention depend on trust and communication.